StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Promacta / Revolade (eltrombopag by Quarter

Promacta / Revolade (eltrombopag — immune thrombocytopenia ITP & aplastic anemia) ($M)

QuarterlyAnnual

Novartis Promacta / Revolade (eltrombopag: $142M in Q3 2026, down 60.8% from a year earlier. That is the lowest of the 35 quarters on record here.

Latest, Q3 2026
142
Period ended Sep 30, 2026
Change on a year earlier
-60.8%
362 in Q3 2025
History
35 quarters
Since Q4 2017
Sources
27
Documents cited below

Where the Q3 2026 figure comes from

“|| Promacta/Revolade 4 | 142 | 362 | – 61 | – 61”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPromacta / Revolade (eltrombopag — immune thrombocytopenia ITP & aplastic anemia) ($M)Year on yearSource
Q3 2026Sep 30, 2026142-60.8%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 2026179-64.3%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026184-66.3%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 2025226-61.2%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 2025362-36.4%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2025Jun 30, 2025502-7.7%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2025Mar 31, 2025546+5.0%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2024Dec 31, 2024583+3.6%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2024Sep 30, 2024569-1.2%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2024Jun 30, 2024544-6.7%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2024Mar 31, 2024520-4.9%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2023Dec 31, 2023563+4.3%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2023Sep 30, 2023576+10.1%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2023Jun 30, 2023583+9.2%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2023Mar 31, 2023547+11.4%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2022Dec 31, 2022540+4.2%Novartis Form 6-K (0001370368-24-000007) ↗

Breakdown

What makes up promacta / Revolade (eltrombopag

Cite this data

StockData. (2026). Novartis Promacta / Revolade (eltrombopag ($M), quarterly Q4 2017–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-promacta-revolade

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.